Abdominal aortic aneurysm (AAA) is a common cause of morbidity and mortality and has a significant heritability. We carried out a genome-wide association discovery study of 1866 patients with AAA and 5435 controls and replication of promising signals (lead SNP with a p value < 1 3 10 À5 ) in 2871 additional cases and 32,687 controls and performed further follow-up in 1491 AAA and 11,060 controls. In the discovery study, nine loci demonstrated association with AAA (p < 1 3 10 À5 ). In the replication sample, the lead SNP at one of these loci, rs1466535, located within intron 1 of low-density-lipoprotein receptor-related protein 1 (LRP1) demonstrated significant association (p ¼ 0.0042). We confirmed the association of rs1466535 and AAA in our follow-up study (p ¼ 0.035).
Introduction
as 0.7. [3] [4] [5] This strong genetic determination in the etiology of AAA has led to multiple candidate gene association studies of AAA, the majority of which have yielded findings that have not been replicated in independent cohorts, but with meta-analysis suggesting common variants in ACE (MIM 106180), MTHFR (MIM 607093), and MMP9 (MIM 120361) might all be contributory. 6 Two replicated loci for AAA have been identified on 9p21.3 7 (which is also associated with coronary artery disease [MIM 611139] and intracranial aneurysm [MIM 611892]) and in DAB2IP (MIM 609205) on 9q33.2 (also associated with early-onset myocardial infarction, venous thromboembolism, and peripheral arterial disease). 8 Other risk factors for AAA include age, male gender, and tobacco smoking. [9] [10] [11] By contrast, diabetes has been shown to be a negative risk factor for AAA, 11 whereas hypertension and hypercholesterolaemia, which are strong risk factors for other arterial diseases, are inconsistent risk factors for AAA. The strong heritability of AAA and the low odds ratio for currently identified risk alleles suggests that other important risk loci for AAA remain to be identified. In an effort to identify new risk alleles for AAA, we undertook a GWAS in 1866 patients with AAA and 5435 controls and replication of promising signals in 2871 additional cases and 32,687 controls and performed a further follow-up study of 1491 AAA and 11,060 controls.
Material and Methods

Study Design and Subjects
We assembled cases of AAA together with available DNA recruited in eight centers in the UK, Australia, and New Zealand and also samples from the United Kingdom Small Aneurysm Trial (Table S1 , available online) none of which had been used in any previous genome-wide association study (GWAS) of AAA cases were recruited from inpatient populations, outpatient clinics, or population screening programs in the participating centers. AAA ascertainment (infrarenal aortic diameter of >30 mm) was by either ultrasonography or by cross-sectional imaging except for patients who presented with acute rupture and for whom it was assumed that the AAA was >5.5 cm. Some of the centers also collected controls screened as being free of AAA by ultrasonography (Table S1 ). In addition to these assembled samples, control data from the Wellcome Trust Case Control Consortium (WTCCC) 2 study were obtained. The study flow is shown in Figure S1 . All samples contributing to this study were collected under the approval of the ethics committee responsible for each center and informed consent was obtained from all individuals.
A genome-wide discovery study was performed by comparing data from 1866 cases with AAA and 5435 unscreened controls from the WTCCC2 study consisting of samples from the 1958 British Birth Cohort and from the UK National Blood Service. The lead SNP for each locus identified in the discovery study with a p value less than 1 3 10 À5 was tested for replication by genotyping 1579 independent AAA cases and 2184 screened controls. In silico replication data for these lead SNPs from the discovery study was obtained from a previously published, independent GWAS of 1292 individuals with AAA and 30,503 controls. 8 A follow-up study of SNPs demonstrating association with AAA in the replication studies was performed in independent samples (11,090 controls and 1491 AAA) from the Copenhagen City Heart Study and the Viborg Country AAA screening program and samples collected by two of the contributing centers during the conduct of the discovery and replication studies.
Genotyping
DNA samples for the discovery and replication studies were processed at the Wellcome Trust Sanger Institute. Genomic DNA was quantified by PicoGreen assay and quality control assured by both agarose gel electrophoresis and Sequenom iPLEX genotyping of 29 SNPs and four gender markers. Genotyping for the discovery study was performed with Illumina 1.2M (controls) or 670K (AAA) BeadChips. Raw intensity data were normalized with BeadStudio, and genotypes were called concurrently from the combined case control data set with the Illuminus algorithm. 12 Replication study genotyping was performed with Sequenom's iPLEX assay. Follow-up studies of rs1466535 in the samples from Copenhagen, Leeds, Otago, and Viborg were performed with the TaqMan allelic discrimination method (with a predesigned, functionally tested assay). All genomic information was referenced to genome build 37.1/dbSNP build 132.
Quality Control
Quality control (QC) in the discovery study was first performed by exclusion of SNPs with call rates of less than 0.98 and those that demonstrated significant deviation from Hardy-Weinberg equilibrium in the control group (p < 0.0001). Duplicate samples and those that failed genotyping (sample call rate 0.98) were also excluded from further analysis. Genotyping cluster plots for all SNPs with p values less than 1 3 10 À4 were visually inspected to exclude from further analysis positive associations generated by erroneous genotyping or calling. Checks for population stratification were first performed by PLINK 13 identical-by-state clustering and extreme outliers were removed from the analysis. Further checks for population stratification were performed by multidimensional scaling and subsequent analyses were adjusted for the dimensions of this analysis. In total, 29,826 SNPs and 191 individuals (23 AAA and 168 controls) were excluded from the analysis as a result of quality control measures.
Association Analysis
Statistical analyses were performed with PLINK. 13 The association between genotype and AAA was tested with a Cochran-Armitage test for trend in the discovery, replication, and follow-up studies, and Fishers method was used to combine p values in the replication studies. were designed based on genomic sequences surrounding the SNP (Table S2) .
Luciferase Assay A LRP1 promoter construct (previously described 22 
Results
Discovery Stage
Following stringent quality control, we tested 535,296 SNPs for association with AAA in 1866 cases (mean AAA size, 4.8 cm and median age, 72 years) and 5435 unscreened controls (median age in the UK Blood Transfusion Service samples was 45 years and all individuals in the 1958 Birth Cohort were 52 years old at the time of analysis). Identical-by-state clustering identified 23 genomic outliers in the AAA group and 168 in the control group that were excluded from further analyses. Further checks for population stratification were performed by multidimensional scaling ( Figure S2 ) that revealed potential stratification and the analysis was therefore adjusted for the first six dimensions from this analysis. The genomic inflation factor (l) was calculated as 1.096 following these exclusions ( Figure S3 ), and an adjustment for this was applied in subsequent analyses. Following these adjustments, nine loci demonstrated association with AAA at a p value threshold of 1 3 10 À5 ( Figure 1 and Table S5 ) and were taken forward for replication.
Replication Stage
The discovery genome-wide association analysis identified nine loci that demonstrated an association with AAA with a p value < 1 3 10 À5 , and one lead SNP from each of these loci was taken forward for replication. Table 1 ). The regional discovery study association plot and LD plot for 12q13.3 are shown in Figure 2 . None of the other variants taken forward to replication showed significant association (Table S5) In particular SNP rs3019885 (risk-allele frequency [T] ¼ 0.51) at 8q24.11 reached genome-wide significance in the discovery study (p value 1.24 3 10 À10 ), but there was no consistent evidence for association in the replication samples (Table S5) . Notably for this variant, the observed effect direction in the in silico data from Iceland was reversed compared to the other replication data sets and the discovery study. To ensure that this observation was not due to erroneous calling, we checked the frequencies of a SNP in LD with rs3019885 (rs2938864) in the Iceland data set and found them to be consistent. Because of the lack of replication, this locus was not carried forward for any further analyses. rs1466535 genotypes were determined in a further follow-up sample comprising 1491 AAA and 11060 controls, and this again confirmed the association of rs1466535 and AAA (p ¼ 0.035) ( has a considerable effect on the measured size, this heterogeneity would result in a lack of power to detect any association. This effect is limited by the dichotomization of the data as adopted here. rs1466535[C] frequencies for each center contributing to the discovery and replication studies are shown in Table S6 . Those for the studies contributing to the in silico replication and follow-up studies are shown in Table 1 To assess whether the association of the 12q13.3 locus with AAA is driven by the presence of clinical factors associated with AAA, we performed an analysis with adjustment for self-reported history of hyperlipidaemia; smoking; or diabetes, which has a negative association with AAA, in subjects where this information was available and found that the association was independent of each of these factors (Table S7) . By examining previous genomewide meta-analyses of lipid traits, diabetes, and blood pressure, we also confirmed that there is no association of this locus with these traits (Table S8) . Because AAA and coronary artery disease (CAD [MIM 608320]) often coexist, we also carried out an analysis adjusted for the presence of overt CAD in our subjects and showed that the association with AAA was still significant (Table S7) , and by an examination of the locus in the CARDIoGRAM study 18 we showed that the locus does not show a signal for CAD ( Figure S4 ). These data indicate that the observed association of the locus with AAA is independent of conventional risk factors for AAA and not due to confounding by the concomitant presence of CAD in the cases.
Functional Assessment of rs1466535 SNP rs1466535 is located in the second intron of the low-density-lipoprotein receptor-related protein 1 (LRP1 
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Results for the genome-wide analysis, replication, and follow-up studies of the SNP rs1466535 in LRP1 associated with AAA. Allele frequencies (AF) shown are for the risk (C) allele. Association testing was performed with the Cochran-Armitage trend test (two-tailed) analysis in the discovery study corrected for a genomic inflation factor of 1.096 and the first six components of a multidimensional scaling analysis. Two-tailed Cochran-Armitage trend tests were used in the replication and follow-up studies. The genome-wide discovery study was performed comparing a pooled AAA case set from contributing centers with the WTCCC2 unscreened controls. The laboratory replication study was performed with a pooled case and control set (not all centers contributed both cases and controls to the analysis). The control samples used in the genome-wide analysis, and the studies from Iceland and Copenhagen were not screened for the presence of AAA. The combined analysis was performed by generic inverse variance weighted meta-analysis with a fixed effects model (P het is the p value for Cochrans Q test for heterogeneity). The overall combined analysis of the discovery, replication and follow-up studies is shown in bold type.
[MIM 107770]) gene ( Figure 2 ). There are no known nonsynonymous SNPs or splice-site variants in linkage disequilibrium (r 2 > 0.2) with rs1466535. We therefore examined whether rs1466535 was associated with expression of any of the genes at the locus. Expression QTL data sets were available for liver and two arterial tissues (the internal mammary artery and ascending aorta). There was a trend toward increased LRP1 expression with the rs1466535 CC genotype in all arterial tissues with a significant (p ¼ 0.029) 1.19-fold (1.04-1.36) increase in LRP1 expression level in CC homozygotes compared to TT homozygotes in aortic adventitia ( Figure S5 and Table 2 ). SREBP-1 is known to play a role in transcriptional regulation of LRP1. 22 We noted that there was sequence homology between the SREBP-1-binding sequence and the region containing rs1466535. To assess whether rs1466535 affects SREBP-1 binding, we performed an electrophoretic mobility-shift assay (EMSA) and found selective binding of nuclear extract from Huh7 cells to an oligonucleotide representing the C allele that was competed out by excess amount of a probe competitor for SREBP-1 ( Figure 3 ). These results indicate that the rs1466535 T allele might disrupt a binding site for SREBP-1. In order to determine the possible transcriptional effect of the rs1466535 variant, a luciferase reporter system was created whereby the LRP1 promoter was inserted upstream of luciferase and the sequence containing the two different genotypes of rs1466535 were placed downstream, in both 
purple circle, the other SNPs typed in the discovery study are shown as filled circles with the color corresponding to their linkage with rs1466535. The solid blue line shows the regional recombination rate (right axis). Below the regional association plot is the LD plot for the same region with the standard D'/LOD Haploview color scheme. rs1466535 is highlighted by green lines. Tissue samples were obtained from 316 patients undergoing aortic valve surgery; 572 unique tissue samples were analyzed. Extracted RNA was hybridized to Affymetrix ST 1.0 Exon arrays and obtained scans were RMA normalized and log2 transformed. DNA was extracted from circulating blood cells and hybridized to Illumina 610w-Quad BeadArrays. rs1466535 genotype was directly measured. Estimates of genotype effect on expression of genes were calculated with an additive linear model. The fold-change is calculated as the difference between the mean expression levels in the CC homozygotes compared to the TT homozygotes. Values greater than one correspond to higher expression in CC homozygous individuals. The results for aortic adventitia are shown in Figure S5 .
reverse and forward directions. Figure S6 shows the relative changes in luciferase activity (compared with the promoteronly construct) between the two different alleles of rs1466535. In both the forward and reverse directions, the T (nonrisk) allele significantly reduced luciferase activity. This finding is consistent with the disruption of SREP-1 binding observed in the EMS assay as well as the LRP1 gene-expression findings in arterial tissue.
Discussion
We report an association of a common and potentially functional variant in LRP1 with risk of AAA. The association with LRP1 with AAA remained after adjustment for cardiovascular risk factors and furthermore, no association of rs1466535 was seen in data from association studies of coronary artery disease, blood pressure, diabetes, or hyperlipidaemia, suggesting that this association is AAA specific rather than associated with cardiovascular disease in general. The risk allele is common (MAF ¼ 0.62) such that roughly 38% of individuals of white European origin will carry two risk alleles and have an approximately 14% higher risk of developing AAA than noncarriers. Interestingly, in South Asian populations, who rarely develop AAA, the allele frequency of the rs1466535 C (risk) allele is lower (0.54), whereas in African American populations (who have a risk of AAA in between that of South Asians and white Europeans) the risk-allele frequency is higher (0.83). 23 Although the association study by itself cannot implicate LRP1 as the causal gene at the locus, other data support its candidacy. Early studies on aneurysmal aortic tissue identified MMP9 as having a prime role in the aneurysmal degradation of the aortic wall. [24] [25] [26] LRP1 has been shown to have a role in the regulation of MMP9 expression in response to tPA binding to the LRP1 receptor, 27 as well as a direct effect on MMP9 cellular processing. 28 In addition to this, LRP1 knockout mice are prone to aneurysm formation. 29 These murine models have demonstrated that LRP1 is essential for the maintenance of vascular wall integrity, particularly in the presence of high plasma lipid levels, 30 and that this effect is mediated via PDGF receptor beta and Smad signaling. 29 Paradoxically, we observed higher LRP1 expression in aortic tissue in those carrying the risk allele for rs1466535, data supported by the findings from the luciferase assay; therefore, whether the risk of AAA relates to higher or lower expression of LRP1 remains to be established. The magnitude of the observed difference in gene expression between genotype groups was small, and therefore caution needs to be exercised in its interpretation. It is possible that this degree of change in expression over a lifetime could have an impact on AAA risk; alternately, interaction of the genotype with other AAA risk factors could result in a much larger change in LRP1 expression in the aneurysmal wall in susceptible individuals. There are no immunohistochemical or expression studies reporting the identification, location, or cellular colocalization of LRP1 in the normal abdominal aortic wall or in aneurysmal aortic tissue, and further investigation of the role of LRP1 in aneurysmal disease is necessary. Similarly, although we found evidence that rs1466535 C allele might create a binding site for SREBP-1, whether this is responsible for the association of the locus with risk of AAA requires further elucidation and more investigation into the determination of the function of this and other SNPs in the region is warranted. LRP1 is a large endocytic transmembrane receptor named because it contains three separate clusters of ligand-binding domains that bear structural similarity to that of the other LDL receptors. It is, however, far larger than the other LDL receptors and has a more diverse range of functions. This variant (rs1466535) has not been associated with circulating lipid levels in large cohort studies, 31 but unrelated SNPs in this region have demonstrated association with triglyceride and HDL levels but without evidence of an increased risk of CAD. 15 The fact that rs1466535 alters expression levels in aortic rather than in hepatic tissue suggests that its effect might not be via circulating lipid levels, although the mechanism whereby the higher expression levels of LRP1 in rs1466535 C-allele carriers leads to an increased risk of AAA is unclear. Previous large-scale genetic association studies for AAA have discovered variants in 9p21.3 and DAB2IP. when the aneurysms reaches a size of more than 5.5 cm, becomes symptomatic, or presents acutely following rupture is the only therapeutic option. Our findings suggest a mechanism contributing to AAA formation via the LRP1 pathway, and exploration of this mechanism could provide future therapeutic approaches to preventing the development and/or progression of AAA.
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